Harbour Biomed Ltd. has received FDA clearance of its IND application to initiate clinical trials in the U.S. with HBM-1007, a fully human monoclonal antibody targeting CD73.
The alpha chain of the IL-3 receptor, CD123, is frequently overexpressed in acute myeloid leukemia (AML) and is considered an attractive target in the treatment of this disease. However, cytotoxic antibodies or T-cell engagers targeting CD123 have shown insufficient clinical efficacy or safety, confirming the need for alternative targeted approaches.
Immunos Therapeutics AG has received full ethical institutional approval from the Human Research Ethics Committee (HREC) and regulatory approval from the Australian Therapeutic Goods Administration (TGA) to conduct a phase I trial of its lead program IOS-1002 in Australia.
Researchers from Guangzhou University of Chinese Medicine have presented preclinical results on a three-component vaccine, MPLA-Tn-KRN7000, as a tumor immunotherapeutic.
Ajinomoto Co. Inc.'s Ajinomoto Bio-Pharma Services has announced a license agreement with Exelixis Inc. to incorporate AJICAP, Ajinomoto's proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' antibody-drug conjugate (ADC) programs for cancer.
A Harvard Medical School research team developed a bifunctional therapeutic vaccine strategy by transforming living tumor cells into a potent agent with direct tumor killing and immunostimulatory abilities.
Minghui Pharmaceutical (Hangzhou) Ltd. and Minghui Pharmaceutical (Shanghai) Ltd. have synthesized antibody-drug conjugates consisting of an antibody covalently linked to exatecan derivatives through a linker.
The advent of bispecific antibodies bridging two different cell types has enabled a new level of cell specificity in cancer biology that has only recently begun to be realized in the clinic.
Researchers at GM Biosciences Inc. have reported developed a novel CD38xCD3 bispecific IgM T-cell engager IGM-2644 with 10 binding sites for human CD38 (Kd=0.27nM; measured by biolayer interferometry) and one anti-CD3 site (Kd=2.1nM) designed to reduce safety concerns.
RSS
.png?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
